Glaukos (NYSE:GKOS) today released 2nd quarter earnings that topped The Street’s expectations for earnings per share and revenue marks, lifting its full year 2016 revenue expectations. The Laguna Hills, Calif.-based company reported profits of $2.3 million, or 6¢ per share, on sales of $28.6 million for the 3 months ended June 30. Glaukos saw a huge […]
Glaukos
Former AcuFocus CEO Mazzo moves to head Ophthamology at Zeiss | Personnel Moves, July 28, 2016
Former AcuFocus CEO Mazzo moves to head Ophthamology at Zeiss Carl Zeiss Meditec (ETR:AFX) said this week it tapped ex-AcuFocus CEO James Mazzo as the global president of its ophthalmology business as well as managing the entire company’s U.S. sales and service center. Mazzo comes from a 3-year run as president and CEO at AcuFocus, where […]
Flex taps ex J&J med device R&D exec Carlson for Flex Med Solutions prez | Personnel Moves April 26, 2016
Flex taps ex J&J med device R&D exec Carlson for Flex Med Solutions prez Flex (NSDQ:FLEX) said it hired ex-Johnson & Johnson (NYSE:JNJ) innovation portfolio veep as its new president of Flex Medical solutions. The position will put Carlson in charge of the company’s $8 billion research & development budget across pharmaceuticals, medical devices and consumer […]
Glaukos wins Japanese nod for iStent glaucoma device
Glaukos (NYSE:GKOS) said today that the Japanese Ministry of Health, Labor & Welfare approved its iStent device for treating glaucoma. Laguna Hills, Calif.-based Glaukos said the approval covers use of the iStent in conjunction with cataract surgery, making it the 1st within-the-eye micro-invasive glaucoma surgery device to hit the market in Japan. The device is designed to be […]
Glaukos taps direct sales force for Canadian iStent launch
Glaukos (NYSE:GKOS) said today it created a direct sales organization to commercially launch its iStent inject trabecular micro-bypass stent for alleviating intra-ocular pressure. The iStent Inject is made from non-ferromagnetic titanium and coated in heparin, designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP, the company said. “The advent […]
Glaukos touts 3-year iStent study data
Glaukos (NYSE:GKOS) said today data from a 3-year study of its iStent Trabecular micro-bypass stent indicated that it, along with cataract surgery, lowered mean intraocular pressure 36% and reduced mean glaucoma medications by 86% 3 years post-surgery. The study reported a mean IP of 14.99 mmHg in 39 patients monitored after treatment for 3 years, compared […]
FDA clears Glaukos Phase II iDose drug-eluting eye implant trial
Glaukos (NYSE:GKOS) said today it won a nod from the FDA for an investigational new drug Phase II study of its Travoprost intraocular implant utilizing the company’s iDose delivery system for patients with glaucoma. The iDose system is injected through a clear corneal incision and secured in the anterior chamber to continuously elute therapeutic levels of […]
Glaukos submits IND for Travoprost eluting iDose
Glaukos (NYSE:GKOS) said it submitted an Investigational New Drug application to the FDA for its Travoprost intraocular implant delivered with the company’s iDose delivery system to reduce elevated intraocular pressure in patients with glaucoma. The Travoprost intraocular implant is injected through a clear corneal incision and secured in the anterior chamber, where the iDose system provides […]
Glaukos touts 3-year data from iStent trial
Glaukos (NYSE:GKOS) today released data from a 3-year study of its iStent travecular micro-bypass stent, touting sustained reductions in intra-ocular pressure after treatment with 2 of the devices. The study was published in the November issue of the Clinical Ophtalmology journal, the company said. The iStent trabecular micro-bypass stent is a tiny titanium stent designed to […]
Glaukos, Transcend Medical settle spat over eye stent patents
Glaukos (NYSE:GKOS) said yesterday that it agreed to settle a patent infringement lawsuit brought by eye stent rival Transcend Medical. The agreement, in which both sides agree not to sue for patent infringement, calls for Transcend to pay a 1% royalty on sales of its Cy-Pass micro-stent until April 2022, with the total amount capped at $6 […]
Trial on tap in Transcend Medical’s patent spat with Glaukos
A federal judge last week said a jury will decide whether Glaukos (NYSE:GKOS) tried to hide the role of 1 of the inventors of its eye stent in patent filings, in a lawsuit with rival Transcend Medical. In 3 decisions issued Sept. 18, Judge Mitchell Goldberg of the U.S. District Court for Delaware ruled that Transcend’s CyPass device does not infringe the Glaukos […]